Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors

Add time:07/26/2019    Source:sciencedirect.com

We report the design and synthesis of a series of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as orally bioavailable small molecule inhibitors of renin. Compounds with a 2-methyl-2-aryl substitution pattern exhibit potent renin inhibition and good permeability, solubility, and metabolic stability. Oral bioavailability was found to be dependent on metabolic clearance and cellular permeability, and was optimized through modulation of the sidechain that binds in the S3sp subsite.

We also recommend Trading Suppliers and Manufacturers of 2-CHLORO-N-(3-ETHOXYPROPYL)ACETAMIDE (cas 10263-65-7). Pls Click Website Link as below: cas 10263-65-7 suppliers

Prev:Carcinogenicity and nephrotoxicity of 2-amino-, 1-amino- 2-methyl-, and 2-methyl-1-nitro-anthraquinone
Next:Determination of CALCIUM SULFATE HEMIHYDRATE (cas 13397-24-5) Modification by X-ray Diffraction Analysis)